FDA Approves Amivantamab-vmjw for Non-small Cell Lung Cancer

On March 1, the US Food and Drug Administration (FDA) approved amivantamab-vmjw in combination with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test.

For more information read the FDA announcement and the Janssen announcement. 

Posted 3/8/2024